Form 4: BioMarin Director Elaine Heron Reports Stock Transactions
SEC Form 4 Filing
Director Elaine Heron reported the acquisition and disposal of BioMarin Pharmaceutical Inc. (BMRN) common stock on June 3, 2024, according to a Form 4 filing with the SEC.
Summary
- On June 3, 2024, Elaine Heron, a director of BioMarin Pharmaceutical Inc. (BMRN), engaged in transactions involving the company's common stock.
- Heron acquired 5,047 shares of common stock through the exercise of stock options at a price of $63.10 per share.
- Simultaneously, she disposed of 4,168 shares to cover tax obligations at a price of $76.41 per share.
- Following these transactions, Heron directly owns 97,720 shares of BioMarin common stock.
- She also holds options to purchase 0 shares of common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document simply reports stock transactions by a company director, which is a routine activity.
Industry Context
Form 4 filings are standard disclosures required by the SEC when corporate insiders, such as directors and officers, trade their company's stock. These filings provide transparency into insider transactions, which can be informative for investors.
Stakeholder Impact
- The transactions may provide insights to shareholders regarding insider sentiment, but the impact is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 09/04/2014 | Original date of stock option grant. |
| 06/03/2024 | Date of stock option exercise and stock disposal. |
| 06/04/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.